- AustraliaNorth AmericaWorld
Investing News NetworkYour trusted source for investing success
- Lithium Outlook
- Oil and Gas Outlook
- Gold Outlook Report
- Uranium Outlook
- Rare Earths Outlook
- All Outlook Reports
- Top Generative AI Stocks
- Top EV Stocks
- Biggest AI Companies
- Biggest Blockchain Stocks
- Biggest Cryptocurrency-mining Stocks
- Biggest Cybersecurity Companies
- Biggest Robotics Companies
- Biggest Social Media Companies
- Biggest Technology ETFs
- Artificial Intellgience ETFs
- Robotics ETFs
- Canadian Cryptocurrency ETFs
- Artificial Intelligence Outlook
- EV Outlook
- Cleantech Outlook
- Crypto Outlook
- Tech Outlook
- All Market Outlook Reports
- Cannabis Weekly Round-Up
- Top Alzheimer's Treatment Stocks
- Top Biotech Stocks
- Top Plant-based Food Stocks
- Biggest Cannabis Stocks
- Biggest Pharma Stocks
- Longevity Stocks to Watch
- Psychedelics Stocks to Watch
- Top Cobalt Stocks
- Small Biotech ETFs to Watch
- Top Life Science ETFs
- Biggest Pharmaceutical ETFs
- Life Science Outlook
- Biotech Outlook
- Cannabis Outlook
- Pharma Outlook
- Psychedelics Outlook
- All Market Outlook Reports
Acura Pharmaceuticals Announces Second Quarter 2018 Financial Results
Acura Pharmaceuticals (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018. As quoted in the press release: The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, compared to a …
Acura Pharmaceuticals (OTCQB:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and six months ended June 30, 2018.
As quoted in the press release:
The Company reported a net loss of $2.8 million or $0.13 per diluted share for the six months ended June 30, 2018, compared to a net loss of $1.7 million or $0.15 per diluted share for the same period in 2017. For the second quarter 2018, the Company reported a net loss of $1.3 million or $0.06 per diluted share compared to a net loss of $2.2 million or $0.18 per diluted share for the same period in 2017.
For the six months ended June 30, 2018, the Company recorded $0.3 million in royalty revenue as compared to $0.1 million for the same period in 2017. For the six month period ended December 31, 2017, the Company also recorded $2.5 million in license fee revenue derived from the March 2017 license agreement with MainPointe Pharmaceuticals, LLC, whereas we licensed our NEXAFED product line to them and $0.1 million in each of NEXAFED® product line net sales and collaboration revenue.
Latest News
Investing News Network websites or approved third-party tools use cookies. Please refer to the cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.